Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 8, 2021February 8, 2021

High Pain Sensitivity in Patients Linked to Worse Clinical Outcomes

News

People with axial spondyloarthritis (axSpA) who had higher pain sensitivity were more likely to have worse clinical outcomes, according to a study that found chronic pain to be common in ... Read more

November 2, 2020November 2, 2020

Gilead Suspends Enrollment in Phase 3 Trials of Filgotinib in AS

News

Gilead Sciences has suspended enrollment in two Phase 3 trials studying the effects of filgotinib, an anti-inflammatory therapy currently being investigated in several inflammatory conditions, in patients with ankylosing spondylitis ... Read more

August 10, 2020August 10, 2020

nr-axSpA Given Diagnostic Code on International Classification of Diseases

News

Non-radiographic axial spondyloarthritis (nr-axSpA) has been given a diagnostic code, M46.80, that will be used to identify the condition in the 10th edition of the International Classification of Diseases, Clinical ... Read more

February 3, 2020February 3, 2020

Early Low Blood Levels of Humira and Antibodies Against It Predict Therapy’s Failure, Study Says

News

Low levels of Humira (adalimumab) early in the course of treatment and the presence of neutralizing autoantibodies in the blood of people with ankylosing spondylitis (AS) are associated with failure to ... Read more

January 27, 2020January 27, 2020

Cosentyx Continues to Ease Symptoms Through 3 Years of Use, New Trial Data Show

News

Treatment with Cosentyx (secukinumab) continues to be safe and to ease symptoms in people with active ankylosing spondylitis (AS) through three years of use, new data from a Phase 3 ... Read more

December 12, 2019December 12, 2019

Simponi Aria Leads to Sustained Improvements in Quality of Life for Adults with Active AS, Phase 3 Trial Shows

News

Treatment with Simponi Aria (golimumab) led to clinically meaningful improvements in health-related quality of life in adults with ankylosing spondylitis after four months — benefits that were maintained over one ... Read more

November 18, 2019November 18, 2019

Erelzi Safe in AS, Eases Disease Activity in Rheumatoid Arthritis, Real-World Data Show

News

Treatment with Erelzi (etanercept) is well-tolerated by people with ankylosing spondylitis (AS) and other rheumatic diseases, including rheumatoid arthritis (RA) and progressive psoriatic arthritis, an early analysis of a real-world study suggests. The ... Read more

October 31, 2019October 31, 2019

Likelihood of Gout May Be More Common in AS Patients, Study Reports

News

Gout —a common, painful form of arthritis that causes swollen, red, hot, and stiff joints — may be more common in people with ankylosing spondylitis (AS) than in the general population, ... Read more

September 19, 2019September 19, 2019

Diffusion-weighted Imaging Useful to Identify Axial Spondyloarthritis

News

A specific type of MRI called diffusion-weighted imaging is sensitive enough to identify patients with early signs of axial spondyloarthritis, a study has f0und. Results of the study, “Diffusion-weighted Imaging ... Read more

August 29, 2019August 29, 2019

Pilates Training May Be Beneficial for AS Patients, Study Finds

News

A physical intervention program based on pilates training may be beneficial for people with ankylosing spondylitis, a study finds. The research, “One Year of Pilates Training for Ankylosing Spondylitis: A ... Read more